Literature DB >> 20805264

Improving type 1 diabetes after treatment of immune thrombocytopenia with rituximab: killing two birds with one stone.

Laura Quintana, Juan A Paniagua, Daniel Gil-Contreras, Victor Jimenez-Yuste, Antonio Torres, Francisco Velasco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20805264     DOI： 10.2337/dc10-0959

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  4 in total

Review 1.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 2.  B cell-targeted immunotherapy for type 1 diabetes: What can make it work?

Authors:  Abdel Rahim A Hamad; Rizwan Ahmed; Thomas Donner; Georgia Fousteri
Journal:  Discov Med       Date:  2016-03       Impact factor: 2.970

3.  TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model.

Authors:  Sha Sha; James A Pearson; Jian Peng; Youjia Hu; Juan Huang; Yanpeng Xing; Luyao Zhang; Ying Zhu; Hongyu Zhao; F Susan Wong; Li Chen; Li Wen
Journal:  Diabetes       Date:  2020-11-05       Impact factor: 9.461

4.  Immune Thrombocytopenic Purpura and Gastritis by H. pylori Associated With Type 1 Diabetes Mellitus.

Authors:  Carlos Culquichicón-Sánchez; Ricardo Correa; Igor Flores-Guevara; Frank Espinoza Morales; Christian R Mejia
Journal:  Cureus       Date:  2016-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.